306 results about "A549 cell" patented technology

The invention discloses 4-(benzofuran-5-yl)-2-benzal aminothiazole as shown in a chemical structural formula I. The preparation method of the 4-(benzofuran-5-yl)-2-benzal aminothiazole is as follows: 1-(7-hydroxy / alkoxy-2,2-dimethyl-2,3-dihydro-benzofuran-5-yl) butanone is subject to bromination and reacts with thiourea to obtain 4-(7-hydroxy / alkoxy-2,2-dimethyl-2,3-dihydro-benzofuran-5-yl)-2-aminothiazole which reacts with aromatic aldehyde to prepare the 4-(benzofuran-5-yl)-2-benzal aminothiazole. The 4-(benzofuran-5-yl)-2-benzal aminothiazole has good activity inhabiting activity on Hela cells, human liver cancer cells (Bel 7402 cells) and lung carcinoma cells (A549 cells) and can be used for preparing the antineoplastic agent.

The invention relates to a method for high selective identification of aluminum ions and tin ions in water phase by using a water-soluble porphyrin probe. According to the method, an ultraviolet-visible spectrophotometer and a fluorescence spectrophotometer are used for detecting the characteristic absorption peak and emission peak of water-soluble porphyrin solution to red shift to certain wavelength respectively to identify the existence of aluminum ions or tin ions in water phase; and fluorescence intensity of human lung carcinoma A549 cells are observed under an upright fluorescent microscope to judge the existence of aluminum ions. In the invention, the sensitivity is high, and rapid detection can be realized; the porphyrin probe has a simple structure and is easy to prepare, and both excitation wavelength and emission wavelength are within visible region; the operation is simple, the fabrication cost is low, and the reagent used and the operation process have no toxic and side effects; and the probe has good selectivity to aluminum ions or tin ions, metal ions such as natrium ions, kalium ions, magnesium ions, copper ions, lead ions and the like have no interference on detection, and the invention can realize detection of aluminum ions in cells.

The invention discloses polypeptide for specifically targeting a lung cancer cell and an application thereof. The polypeptide for specifically targeting the lung cancer cell has an amino acid sequence shown as SEQ ID NO.1, and is prepared by screening on the surface of the human lung cancer cell by an ex-vivo bacterial random polypeptide library exhibiting method and a flow cell sorting method. The polypeptide for specifically targeting the lung cancer cell can be applied to preparation of lung cancer diagnosing tracer, lung cancer cell detecting reagent and the like. The polypeptide for specifically targeting the lung cancer cell can be combined with a lung cancer A549 cell specifically, is not combined with a normal lung cell and other tumor cells; and the preparation method is simple, feasible and applicable to large-scale industrial production. The polypeptide for specifically targeting the lung cancer cell provides important theoretical and practical basis for early diagnosis, targeting therapy of the lung cancer and the like, and has a wide application prospect.

The present invention provides methods for adapting cells, such as A549 cells, to growth in serum-free and animal material-free medium suspension culture. The present invention provides methods for preparing viruses, such as adenovirus, from the A549 cells adapted for growth in serum-free and animal material-free medium in suspension culture.

The invention provides a compound having anticancer activity, which is obtained by cooperation of Norabieta cantharidin and platinum (IV) and modification of a piperazine derivative. The compound is characterized in that a Norabieta cantharidin piperazine derivative ligand is introduced, thereby cytotoxicity of a platinum (IV) compound is reduced, and high antineoplastic activity is provided. The result of the cytotoxicity experiments shows that the provided platinum (IV) compound has less destruction to normal mice fibroblast L929, but has good killing effect to cancer cells such as human breast cancer MCF-7 cell, human cervical carcinoma HeLa cell and human lung adenocarcinoma A549 cell, so that the compound having anticancer activity is capable of reducing the system toxicity and having equal anticancer activity with cisplatin. The compound having anticancer activity has good killing effect by aiming at cisplatin resistance human lung adenocarcinoma A549 / DDP cell. Therefore, the toxicity is reduced, the cisplatin resistance can be reversed, and anticancer effect of the platinum medicines can be increased.

The invention discloses a triphenylphosphine-polyethyleneglycol 1000 vitamin E succinate (TPGS 1000-TPP) conjugated compound, and a preparation method and application thereof. The structural formula of the compound is disclosed as Formula I. The preparation method of the conjugated compound comprises the following steps: (1) reacting triphenylphosphine and 6-bromocaproic acid to obtain 5-carboxyamyltriphenylphosphonium bromide disclosed as Formula IV; and (2) carrying out esterification reaction on the 5-carboxyamyltriphenylphosphonium bromide disclosed as Formula IV and polyethyleneglycol 1000 vitamin E succinate to obtain the conjugated compound disclosed as Formula I. The invention also discloses a mitochondrion targeted taxol liposome comprising the conjugated compound. The drug effect test proves that the mitochondrion targeted taxol liposome has strong cell toxicant action in the in-vitro cell experiment and in-vivo transplantation tumor model of human lung adenocarcinoma A549 cells and drug-resistant A549 / cDDP cells thereof and can enhance the antitumor effect of taxol on drug-resistant A549 / cDDP cells.

The invention discloses a DQA-PEG 2000-DSPE (Dequalinium Chloride-Polyethylene Glycol-Distearoyl Phosphatidyl Ethanolamine) conjugated compound and resveratrol liposome modified thereby. The structural formula of the compound is shown by a formula I. In terms of composition, the resveratrol liposome comprises resveratrol and a fat material, wherein the mass ratio of the resveratrol to the fat material is (1:20)-(1:40); and the fat material consists of egg yolk lecithin, cholesterol and the compound shown by the formula I in the molar ratio of (63-67):(18-22):(2-4.35) in sequence. Pharmacodynamic tests prove that mitochondrial targeted resveratrol liposome has an extremely strong cell toxic effect in in-vitro cell experiments of human lung adenocarcinoma A549 cells and drug-resistant A549 / cDDP cells thereof, a tumor sphere model and an in-vivo transplantation tumor model and can penetrate through the core of the tumor sphere. The anti-tumor effect of vinorelbine liposome on the drug-resistant A549 / cDDP cells can be obviously improved by combining the resveratrol liposome with the vinorelbine liposome for use (formula I).

The invention discloses a method for culturing lung cancer stem cells under 3D culture conditions and belongs to the field of cell culture methods. The method comprises the following steps of placing human lung adenocarcinoma cell line A549 in an incubator for culturing with a RPMI-1640 complete culture medium containing 10% fetal calf serum, taking a cell suspension in a logarithm growth period, adjusting the concentration of the cells to 5*10<4>cells / ml and adding 200 mu L / well into a 96-well plate in which 50 mu L / well BME is spread; on the third day, changing the culture medium for the A549 cells with a RPMI-1640 complete culture medium containing IGF-1 and FGF and further culturing; digesting BME through a proteolytic enzyme, recovering the A549 cells from a recovery liquid and finally identifying the cells. By such design, the A549 cells form cloned mass similar to in-vivo tumor mass in vitro, which is closer to the three-dimensional growth state in the human body and thus the stable separation and effective amplification of stem cells are achieved. The cancer stem cells capable of resisting anticancer drugs are screened.

The invention relates to a building method of a cell strain for stably expressing NS1 (non-structural 1) protein. An NS1 gene is inserted in an EcoR I polyclone site of a pLenti-CMV-EGFP-3Flag-PGK-Puro carrier; a built pLenti-CMV-NS1-EGFP-3Flag-PGK-Puro recombinant plasmid and a virus packaging plasmid are used for 293T cell cotransfection; culture, toxin elimination, virus liquid supernatant collection and filtering are performed to obtain recombinant lentivirus liquid. Packaged recombinant lentivirus infection A549 cells are subjected to puromycin screening, immunofluorescence and Western blot identification to obtain the cell strain for stably expressing NS1 protein. A recombinant lentivirus system is used for preparing the cell strain fusing tag protein capable of stably expressing the NS1 protein. The cell strain provides a good tool for studying the biological function of the NS1 protein.

The invention discloses a new drug against lung cancer and an extraction separation method of the new drug. The extraction separation method comprises the following steps of: performing homogenate, 70% alcohol extraction, deproteinization by trichloroacetic acid and vacuum freeze-drying on whole mollusk Vaginulus alteFerussac, performing chromatographic separation by gel columns repeatedly for multiple times, detecting molecular weight, molecular organization and primary molecular structures of the components, and conducting in-vivo and vitro anticancer pharmacology experiments to obtain an anti-lung-cancer active ingredient JK of the Vaginulus alteFerussac. Animal experiments prove that the heavy inhibition ratio of the JK on human-derived lung adenocarcinoma A549 cytoma reaches 54.37%; the heavy inhibition ratio of the JK on human-derived small cell lung cancer CNI-H446 cytoma reaches 59.73%; the heavy inhibition ratio of the JK on rat-derived Lewis lung cancer tumor reaches 49.49%; and the combination of the JK and cinobufotalin generates a synergistic effect. The experiments also prove that the JK has anticancer mechanisms shared by multiple Chinese traditional medicines, is compound with multiple target points, and relates to the synthesis of nucleic acid for inhibiting lung cancer cells, induction of lung cancer apoptosis, angiogenesis for restraining lung cancer tissue and the adhesion of the cancer cells on a vascular wall after the cancer cells invade blood circulation.

The invention provides a new use of beta-sitosterol in preparation of a medicine for treating or preventing influenza A, and further provides the medicine for treating or preventing the influenza A. The medicine comprises an active component of the beta-sitosterol. The inventor of the application finds that the beta-sitosterol has a significant inhibitory activity for an inflammatory reaction mediated by influenza A virus. The fluorescence real-time quantitative polymerase chain reaction (PCR) is used for confirming that the beta-sitosterol can obviously inhibit abnormal expressions of A549 inflammatory cytokines infected by an H1N1 virus and show a dose-dependent relationship; the Western blotting is adopted to confirm that the beta-sitosterol can inhibit activation with host inflammation related signaling pathways and show the dose-dependent relationship. Animal experiments show that the beta-sitosterol can significantly inhibit lung injuries and inflammations induced by influenza virus A (H1N1).

The invention relates to an A549 nude mouse model of stably expressed luciferase and building and application thereof. The nude mouse model leads firefly luciferase genes to human lung adenocarcinoma A549 cell strains through the gene recombination technology and lentivirus infection, tumor clone cell strains of the stably expressed luciferase are obtained through subcloning screening, and recombinational A549 cells are inoculated in a mouse to obtain the A549 nude mouse model. Compared with a traditional tumor model drug effect detection method, the A549 nude mouse model enables observation to be visual and convenient, can be used for somatoscopy without damaging animals, is reliable in result, and has good application prospect.

The invention belongs to the technical field of medicines, relates to compounds having antitumor activity and having specific chemical structures, and particularly relates to pyrimidine type antitumorcompounds having a 1,3,4-oxadiazole structure and a preparation method and application thereof. The general structure formula of the pyrimidine type antitumor compounds is shown as follows in the description. The novel compounds greatly improve antitumor effects, and have more excellent anti-proliferation capability for human lung cancer A549 cells when compared with pyrimidine acylhydrazine compounds. Synthetic steps are simplified in a synthesis process, thus making future industrial production possible.

The invention discloses gramicidin, isomer thereof and application thereof. The structure is Ac-Asp-Arg-Val-Tyr-Ile-His-Pro-NH2 and Ac-Asp-Arg-Val-Tyr(D)-Ile-His(D)-Pro. Two modified construction bodies have biological activity which is similar to angiotensin 1-7 and capable of promoting human umbilical vein endothelial cells (HUVEC) to release nitrogen oxide (NO) for migration, forming a tubelet and restraining A549 cell growth. Simultaneously, the modified construction bodies have degradation capability of three degradation enzymes including ACE, NEP and AP, thereby ensuring that the modified construction bodies have longer half-life periods than the angiotensin 1-7. The modified construction bodies are simple to obtain and provide important application value for development of novel polypeptide drugs for treating cardiovascular and cerebrovascular diseases.

The invention relates to a semicarbazide dihydroartemisinin derivative (general formula I) or a pharmaceutically-acceptable hydrate and salt of the semicarbazide dihydroartemisinin derivative, wherein R is H and various kinds of alkyls; the alkyls can be randomly substituted by substituent groups of halogens, amino groups, substituted amino groups, carboxyls, hydroxyls, ester groups, cyano groups, nitryls, aryls and substituted aryls; and Z is O, S and NH. The semicarbazide dihydroartemisinin derivative disclosed by the invention has a remarkable effect on inhibiting Hela and A549 cells so as to have a relatively-good anti-tumor effect. The invention discloses a preparation method of the semicarbazide dihydroartemisinin derivative.

The invention discloses a compound shown as a chemical structural formula I or II and pharmaceutically acceptable salt thereof. The compound shown as the chemical structural formula I or II has a following preparation method that 2-toluenyl-1-alkyl-1, 3-butanedione and thiourea take reaction under stirring in organic solvents at 55 DEG C to 80 DEG C under the catalysis of HY acid to obtain 4-alkyl-6-aryl-5-acetyl-2-amino-1, 3-thiazine salt (I.HY), the 4-alkyl-6-aryl-5-acetyl-2-amino-1, 3-thiazine salt is neutralized by alkali to obtain the compound as shown as the formula I, and the compound shown as the formula I is subject to acidylation to obtain the compound shown as the formula II. The compound shown as the formula I or the formula II has good inhibitory activity on human cervical carcinoma cells (Hela cells), human hepatocarcinoma cells (Bel 7402 cells) and human lung adenocarcinoma cells (A549 cells) and can be used for preparing anti-tumor medicine.

The invention provides an anti-tumor metal iridium (III) complex, belonging to the technical field of biological medicine. The chemical formula of the anti-tumor metal iridium (III) complex is [Ir(ppy)2(BDPIP)]PF6. Furthermore, the invention also provides a preparation method of the anti-tumor metal iridium (III) complex and application of the anti-tumor metal iridium (III) complex in anti-tumor drugs. The anti-tumor metal iridium (III) complex has a very strong inhibiting effect for the growth of tumor cells, especially for the growth of cells A549, can induce the apoptosis of the tumor cells, has an IC50 value of 3.6mu M, and can be used as a medicine for treating tumor A549; in vivo tests prove that the tumor inhibiting rate of the anti-tumor metal iridium (III) complex reaches up to 63.84%. The preparation method of the metal iridium (III) complex is high in yield.

The invention discloses an application of berberine in medicine for treating or preventing influenza virus. The application proves that berberine enjoys the good function of resisting influenza virus on MDCK cells infected by A-type influenza virus such as H5N1 and H3N2 and on A549 cells.Meanwhile, the berberine can kill influenza virus to a certain extent, prevent attack from the influenza virusand inhibit cells infected by the influenza virus; the berberine enjoys similar effect to amantadine, a positive control medicine; in addition, the berberine can well inhibit inflammatory responses triggered by the influenza virus and is disclosed to enjoy the prospect of being developed into the medicine for resisting the influenza virus.

The invention discloses application of a small molecule inhibitor DHW-5 of methane sulfonamides in preparation of antitumor drugs, and belongs to the technical field of biological medicine. Accordingto the application, a drug DHW-5 which can effectively inhibit the growth of tumor cells is screened out from small molecule inhibitor libraries of the methane sulfonamides, and can effectively inhibit the proliferation of cervical cancer hela cells, breast cancer BT549 cells, non-small cell lung cancer A549 cells, ovarian cancer SKOV-3 cells and gastric cancer cells SGC-7901, the semi-inhibitoryconcentration are all lower than 9.0 uM, and particularly, the inhibition effect on the breast cancer BT549 cells is the best. The inhibitor can target phosphoinositide 3kinase (PI3K), block the conduction of PI3K signaling pathways, and trigger cycle arrest and endogenous pathways mediated by mitochondria so as to induce apoptosis of the tumor cells. The inhibitor can be used for preparing the antitumor drugs and provides a new idea and mechanism for the research and development of antitumor small molecule drugs of kinase inhibitors.

The invention discloses a conjugate of curcumin and an oligopeptide Arg-Gly-Asp-Ser, a preparation method of the conjugate and the tumor cell proliferation resisting activity, the A549 cell migration and invasion inhibiting effects, the S180 tumor-bearing mouse tumor weight increasing inhibiting activity, the Lewis lung cancer metastasis inhibiting activity, the xylene-induced mouse ear swelling inhibiting activity and the rat thrombus generation inhibiting activity of the conjugate. The conjugate has the following formula (please see the formula in the description).

The invention discloses a medicinal composition for treating non-small cell lung cancer, and relates to the technical field of traditional Chinese medicines. The medicinal composition is prepared from the following active components in parts by weight: 10-15 parts of fructus schisandrae chinensis, 5-10 parts of cordyceps sinensis, 12-16 parts of Chinese angelica, 10-15 parts of radix astragali, 15-20 parts of panax pseudoginseng, 4-6 parts of calculus bovis, 4-6 parts of centipede, 1.5-2.5 parts of cornu cervi pantotrichum, 12-16 parts of radix codonopsis, 6-12 parts of lily and 6-12 parts ofradix platycodonis. After the model rat is subjected to gavage with the medicinal composition disclosed by the invention, the antagonism on the growth of transplanted tumor in nude mice of the human lung cancer A549 cell can be enhanced, thus indicating that the traditional Chinese medicinal composition disclosed by the invention has a very effective inhibiting effect on the growth of cancer cellof the non-small cell lung cancer molding rat.

The invention relates to the effect of miR-451a cells in the non-small cell lung cancer. Migration of A549 cells can be significantly inhibited through overexpression of miR-451a in the A549 cells. By means of the bioinformatics analysis means, it is predicted that translation of the target gene mRNA is inhibited or the target gene mRNA is directly degraded by miR-451a through regional complementation with 3'-UTR of the target gene CAB39 mRNA; it is determined that the CAB39 gene is the target gene of miR-451a through double-luciferase reporter gene system analysis and Western Blot experiment verification. Finally, it is verified through the Transwell Assay and Flow Cytometry Assay experimental means that miR-451a performs the function of inhibiting migration of cells by reducing the CAB39 gene in the A549 cells, and a novel accurate treating researching and treating scheme is provided. By means of the effect, important research guidance and application value is provided for using miRNA for diagnosing and treating the non-small cell lung cancer and searching for drug targets in the fields such as tumor immunotherapy clinically.

Disclosed is a Chinese traditional medicine extractive for resisting lung cancer A549 cells to proliferate, which is composed of the following materials by certain weight ratio: ternate buttercup root, cymose buckwheat rhizome, herba houttuyniae, agrimony, Chinese waxgourd seed, scarlet begonia, brazilwood, safflower, prepared pinellia tuber, arisaema cum bile, root of straight ladybell, polygonatum; the preparing method is that: the above 13 materials are added with water to be decocted and filtered so as to take the filtered liquid out; and then the filtered liquid is condensed to obtain a full extracting liquid 1; and then the extracting liquid 1 is extracted by sherwood oil so as to obtain a prepared extracting liquid 2; and finally, the prepared extracting liquid 2 can be upgraded by macroporous resin, eluted by pure water, and then eluted by ethanol; the eluted liquid is collected for condensing to 10g medicine / ml so as to obtain the Chinese traditional medicine extractive; indicated by the experiment result of pharmacodynamics, the Chinese traditional medicine extractive has obvious effects on resisting the lung cancer A549 cell proliferation.

The invention belongs to the technical fields of medicinal chemistry and polypeptide biology, and relates to an oligopeptide derivative P15 capable of combination of basic fibroblast growth factor (bFGF), wherein the sequence of the P15 is N'-PILQAGLGGGS-NH2-C'. The invention specifically relates to the sequence of the P15, and an application of the P15 in fields of basic research and medicine. The present invention further comprises various peptide derivatives of the P15, wherein the P21 is the peptide derivative of the P15, and the sequence of the P21 is N'-PLLQA TA GGGS-NH2-C'. With combination of the bFGF, the P15 and the P21 can provide good inhibition activities for bFGF-induced NIH3T3 cell proliferation and bFGF-induced Bable / C 3T3 cell proliferation, can significantly inhibit proliferations of bFGF-induced lung cancer A549 cells and bFGF-induced glioma U251 cells, and provide prospects for development into anti-tumor peptide drugs.

The invention discloses a Leu-Asp-Val modified curcumin and oligopeptide conjugate of the following formula, a preparation method thereof, its activity of inhibiting tumor cell proliferation, its effect of inhibiting migration and invasion of A549 cells, its activity of inhibiting S180 tumor-bearing mice tumor weight increase, its activity of inhibiting Lewis lung cancer metastasis, its activity of inhibiting xylene induced mice ear swelling, and further discloses its activity of inhibiting rat thrombosis.

The invention provides an ACE (angiotensin converting enzyme) inhibition peptide with nutrition repairing and cell function activation and a preparation method. The peptide is a small-molecule peptidewhich is separated and extracted from black foods. It finds that the peptide self is an ACR (anti-hypertension) inhibitor, and experiment shows that the peptide has an activation function on TIDCs (tumorindiltrating dendritic cells) induced by melanoma cells, and has a repairing function on A549 cell injury caused by hydrogen peroxide; a medicine made of the small-molecule peptide has the characteristics of being remarkable in clinical effect and small in toxic and side effect; and the preparation method of the food small-molecule peptide extracted by the invention is simple and practical.

The invention discloses enzymolysis polypeptide and use thereof in preparation of a medicine for treating lung adenocarcinoma. The enzymolysis polypeptide is prepared from cicada by the following steps: cleaning the cicada, mincing the cicada into meat paste, adding Protamex compound protease for enzymolysis, wherein the enzymolysis conditions are as follows: the pH value is 6.8-7.2, the enzymolysis temperature is 42-47 DEG C, and the enzymolysis time is 7-9 hours; after the enzymolysis is finished, heating to inactivate the compound protease, and cooling to the room temperature; after the cooling, carrying out centrifugation at a rotation speed of 8000rpm-10000rpm for 20-30 minutes, extracting supernatant, and carrying out freeze drying, so as to obtain freeze-dried powder; dissolving the freeze-dried powder with ultrapure water, separating obtained enzymolysis polypeptide by virtue of ultrafiltration membranes with different molecular weight cut-offs, and carrying out freeze-drying on components obtained through ultrafiltration, so as to obtain enzymolysis polypeptides with different molecular weights. According to the enzymolysis polypeptide, the proliferation of A549 cells of the lung adenocarcinoma can be restrained, the apoptosis of the A549 cells can be promoted, the growth of nude mice transplanted tumors of the A549 cells of the lung adenocarcinoma is remarkably inhibited, and drug resistance of the A549 cells of the lung adenocarcinoma to the enzymolysis polypeptide is unlikely to be produced; and toxicology researches prove that the enzymolysis polypeptide has no toxic and side effects.

The invention discloses a method for extracting an anti-tumor active component from traditional Chinese medicine pericarpium juglantis. The method uses a macroporous resin technology to extract the active component from the traditional Chinese medicine pericarpium juglantis. The component simultaneously has the activity of inhibiting growth of S180 and H22 mice transplanted tumors and inhibiting the proliferation of human lung cancer cell strain A549.

The invention relates to a herba epimedii total flavonoid enzymatic product. Herba epimedii total flavonoid is generated through immobilized helicase, and the enzymatic product has higher antineoplastic activity than the herba epimedii total flavonoid archetype and free enzyme enzymatic product and has high oral absorptivity. The invention further discloses a preparing method of the enzymatic product. The immobilized enzyme is used for enzymolysis of herba epimedii total flavonoid, selected helicase is high in combining efficiency with a fixed carrier and high in stability, the enzymolysis conversion rate is large, the immobilized enzyme can be used circularly, resources can be saved, and green production is achieved. The invention further relates to application of the enzymatic product in antitumous effect, and the herba epimedii total flavonoid enzymatic product obtained through the technical scheme has a remarkable anti-proliferative effect on the human lung cancer cell A549, liver cancer HepG2 cell, breast cancer MCF-7 cell, cervical cancer Hela cell and can be used for treating the lung cancer, liver cancer, breast cancer and cervical cancer.